Navigation Links
Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies

May 22, 2012 (Hackensack, NJ) John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm.

"I'm excited to bring together some of the nation's top immunology experts to review the latest developments and implications of cell therapies in oncology, both in solid and liquid tumors," said Andre Goy M.D., Cancer Center Director, and Chief of lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "This will provide an opportunity to see where the field is going and discuss some of the mechanisms and applications of T-cell manipulation as a promising tool against a number of cancers. The preliminary results seen with these modified T-cells will likely be revolutionary in the treatment of cancer".

The conference, titled "Cell Therapy and Interventional Immunology: Current Developments and Implications", is designed for hematologists, oncologists, physicians, and medical professionals. Given the enormous impact and growing interest in those therapies, the conference will also be offered to patients and caregivers through live online streaming. Speakers will cover the biology and manufacturing aspects of the chimeric antigenic receptor (CAR) modified T-cells as well as other manipulation of T-cells and the immune system, which for the first time, seem to be translating into impressive activity in the clinic.

The conference speakers and presentations include:

  • Catherine Bollard, MBChB, M.D., Professor of Pediatrics, Medicine, and Pathology & Immunology, Texas Children's Cancer Center, Baylor College of Medicine: Anti-EBV T-Cells and CAR T-Cells and Their Applications in Hematological Malignancies
  • Renier J. Brentjens, M.D., Ph.D., Leukemia Service, Memorial Sloan-Kettering Cancer Center: CAR Modified T-Cells for the Treatment of Cancer: Preclinical and Clinical Outcomes
  • Daniel H. Fowler M.D., Senior Investigator, Center for Cancer Research. National Cancer Institute: TH-2 Amplification and Other strategies to Reduce GVHD and Improve Outcome in Allogeneic Transplantations.
  • James N. Kochenderfer, M.D., Assistant Clinical Investigator, Center for cancer Research, National Cancer Institute: Autologous and Donor Derived Anti-CD19 CAR T-Cells Applications in non-Hodgkin Lymphoma and CLL
  • Cameron J. Turtle, M.D., Ph.D., Acting Instructor, University of Washington and Research Associate, Fred Hutchinson Cancer Research Center: Engineered Antigen Presenting Cells and T-Cells for Anti-Cancer Therapy

"Conferences such as this help physicians, medical professionals, as well as patients and caregivers to gain a better understanding of promising new treatment options, resulting in better clinical outcomes," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates, "John Theurer Cancer Center is committed to providing these conferences to improve patient care and education."


Contact: Amy Leahing
John Theurer Cancer Center

Related medicine news :

1. Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency
2. Mirena IUD Lawyers at Gilman Law LLP, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Anticipates Progress in Newly Established Mirena Federal Litigation
3. 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease, Pulmonary Hypertension Association Says
4. Study evaluates effect of different supplements on reducing risk of progression to advanced AMD
5. Nina Brown Launches New Website for Spiritual Progressives
6. Despite superbug crisis, progress in antibiotic development alarmingly elusive
7. Progressive Dental Marketing Is Bringing Online Dental Marketing to Oregon for Dental Professionals Specializing in Laser Dentistry and Dental Implants
8. New findings on the brains immune cells during Alzheimers disease progression
9. Progressive Dental Marketing Is Bringing Online Dental Marketing to Oregon for Dental Professionals Specializing in Laser Dentistry and Dental Implants
10. Progressive Dental Marketing Is Bringing Online Dental Marketing to Washington for Dental Professionals Specializing in Laser Dentistry and Dental Implants
11. Progressive Dental Marketing Is Bringing Online Dental Marketing to Vancouver, B.C. for Dental Professionals Specializing in Laser Dentistry and Dental Implants
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: